Aegerion Pharmaceuticals (AEGR) Highlighted As Today's Perilous Reversal Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Aegerion Pharmaceuticals ( AEGR) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Aegerion Pharmaceuticals as such a stock due to the following factors:

  • AEGR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $32.0 million.
  • AEGR has traded 60,995 shares today.
  • AEGR is down 3% today.
  • AEGR was up 6.5% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AEGR with the Ticky from Trade-Ideas. See the FREE profile for AEGR NOW at Trade-Ideas

More details on AEGR:

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. Currently there are 7 analysts that rate Aegerion Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Aegerion Pharmaceuticals has been 995,500 shares per day over the past 30 days. Aegerion has a market cap of $918.0 million and is part of the health care sector and drugs industry. The stock has a beta of 0.23 and a short float of 34.4% with 8.42 days to cover. Shares are down 56.2% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

5 Stocks Insiders Love Right Now

7 Stocks Under $10 Making Big Up Moves

5 Stocks Under $10 Set to Soar

Wall Street Loses Gains After Fed's Unsurprising June Call

Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy